all report title image
  • Published On : Jun 2022
  • Code : CMI5037
  • Industry : Pharmaceutical
  • Pages : 508
  • Formats :

An allergy is a medical condition where the immune system reacts abnormally when exposed to certain foreign substances. These allergy-producing substances are known as allergens. Allergens can be dust particles, mites, molds, pollens, animal proteins, foods, and medications.

Allergies can be perennial or seasonal. Perennial allergies occur due to specific allergens that cause an allergic reaction throughout the year. Allergens responsible for perennial allergies include pet hair or dander, food, and medication. Seasonal allergies occur due to weather changes that allow growth of mold, insect or grass. Seasonal allergies are caused by airborne allergens such as pollens and ragweed. Symptoms of allergic reactions include itching, runny & blocked nose, watery eyes, wheezing, shortness of breath, swelling in lips, eyes or face, sneezing, and others.

Europe and Japan Allergy Immunotherapy Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to limit growth of the Europe and Japan allergy immunotherapy market, owing to disruption of transportation between the countries. For instance, according to the European Medicines Agency (EMA): 2020, the European medicines regulatory network established the steering group in March 2020 in response to the COVID-19 pandemic. It consists of representatives of EMA, the European Commission, Heads of Medicines Agencies (HMA), and coordination groups for mutual recognition and decentralized procedures for human and veterinary medicines (CMDh and CMDv), as well as risk communication specialists. The steering group does the work of developing methods for the collection and sharing of data on demand for medicines across European Union (EU) and improve the forecasting of demand for medicines.

Due to COVID-19 pandemic, there has been increase in social distancing, maintenance of hygiene, etc. Moreover, practical recommendations have been developed for the improvement of care for allergic patients in daily routine. Also, telemedicine has aroused as a very valuable tool for handling allergic patients.

During the pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) proposed several research papers and clinical recommendations for daily clinical care of allergic patients. One of the most important therapies in allergic patients is allergen immunotherapy (AIT) as the only disease-modifying treatment option in IgE-mediated allergic diseases. According to the guidelines updated by EAACI and the journal ‘Allergy and Its Impact on Asthma’ (ARIA-)initiative outlined practical recommendations on AIT, if COVID-19 is suspected or confirmed, all kinds of AIT should be temporally interrupted as a general rule in infectious diseases. Moreover, if the patient is free of symptoms without evidence of the disease, then sublingual immunotherapy (SLIT) can be administered at home supported by telemedicine. This option can help in maintaining adherence to treatment as well as in follow-up of allergic disease evolution and confirmation of absence of COVID-19.

The Europe and Japan allergy immunotherapy market is estimated to be valued at US$ 1,228.37 Mn in 2022 and is expected to exhibit a CAGR of 8.1% over the forecast period (2022-2030).

CMI table icon

Europe and Japan Allergy Immunotherapy Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,228.37 Mn
Historical Data for: 2018 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 8.1% 2030 Value Projection: US$ 2,293.56 Mn
Geographies covered:
  • Europe: U.K, Germany, Italy, France, Spain, Denmark, Sweden, Poland, Belgium, Netherlands, Russia, Rest of Europe
  • Japan
Segments covered:
  • By Treatment: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT)
  • By Allergy Type: Allergy Rhinitis, Allergy Asthma, Pollen Allergies (Cedar, Birch, Oak, Others), Pet Allergy (Cats, Dogs, Other Pets), Birds Allergy, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Novartis International AG, Merck & Co., Inc., Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., HAL Allergy B.V., Stallergenes Greer, ALK-Abelló A/S, Allergy Therapeutics Plc, Torii Pharmaceutical Co., Ltd., and DESENTUM OY

Growth Drivers:
  • Market players are involved in conducting clinical trials for development of allergy immunotherapy
  • Key players are receiving marketing authorization for their allergy immunotherapy drugs, from regulatory authorities
Restraints & Challenges:
  • Side Effects associated with Sublingual Immunotherapy (SLIT)

Figure 1: Europe and Japan Allergy Immunotherapy Market Share, (%), Analysis, By Treatment Type, 2022

 Europe and Japan Allergy Immunotherapy  | Coherent Market Insights

Market players are conducting clinical trials for development of treatment for allergy immunotherapy. This is expected to drive growth of the Europe and Japan allergy immunotherapy market over the forecast period.

Market players are conducting clinical trials for development of immunotherapy treatment for various allergies like allergic rhinitis, pet allergies, food allergies etc. for instance, the following table shows some of the clinical trials that are being conducted by the market players for allergy immunotherapy.

Title Number of Cases Sponsors Phases Completion Date
A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut Peanut Allergy Intrommune Therapeutics Phase I

August 15, 2022

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults Food Allergy Alladapt Immunotherapeutics, Inc. Phase I / II

December 12, 2022

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization Peanut Allergy Aimmune Therapeutics, Inc. Phase III

June 22, 2022

Oral Immunotherapy for Peanut Allergic Patients Peanut Allergy InnoUp Farma S.L. Phase I / II

June 22, 2022

Open-label Extension Study of ADP101 Food Allergy Alladapt Immunotherapeutics, Inc. Phase I / II

December 26, 2022

 

Key players are engaged in receiving approvals for their products from regulatory authorities and this is expected to drive growth of the Europe and Japan allergy immunotherapy market over the forecast period.

Increasing number of marketing authorizations by regulatory authorities, is expected to increase  growth of market, over the forecast period. For instance, in 2018, HAL Allergy B.V. received the registration of SUBLIVAC Birch 40.000 AUN/ml and SUBLIVAC Trees 40.000 AUN/ml in Germany. The marketing authorizations were granted by German Therapieallergene Verordnung (TAV), which is the German Federal Ministry of Health, which regulates the marketing authorization requirements for the frequent therapeutic allergens.

Europe and Japan Allergy Immunotherapy Market – Restraints

Side effects associated with allergy immunotherapy drugs is expected to hamper growth of the Europe and Japan allergy immunotherapy market, over the forecast period. Side effects associated with sublingual immunotherapy (SLIT) are expected to restrain growth of the Europe and Japan allergy immunotherapy market over the forecast period. The most common adverse effects of sublingual immunotherapy (SLIT) are oral pruritus, ear pruritus, throat irritation, and swelling of the lips, tongue, and pharynx. A smaller percentage of patients may also experience edema of the tongue, uvula, lips, or throat that may occasionally require epinephrine. Furthermore, according to an article published by National Center for Biotechnology Information: 2019, in the U.S., it was reported that 4 to 7% of patients dropped out of the clinical trial due to the adverse effects of immunotherapy for allergies

Europe and Japan Allergy Immunotherapy Market – Regional Analysis

Among regions, Europe allergy immunotherapy market is expected to hold a dominant position during the forecast period, owing to increasing marketing authorization by the regulatory authorities. For instance, in June 2019, ALK-Abelló A/S announced that it successfully completed the marketing authorization procedure for its tree sublingual allergy immunotherapy (SLIT) tablet in 17 European countries. ITULAZAX is expected to be the brand name of the tree SLIT-tablet.

Figure 2: Europe and Japan Allergy Immunotherapy Market (US$ Mn), by Region, 2022

Europe and Japan Allergy Immunotherapy  | Coherent Market Insights

Europe and Japan Allergy Immunotherapy Market – Competitive Landscape

Major players operating in the Europe and Japan allergy immunotherapy market include Novartis International AG, Merck & Co., Inc., Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., HAL Allergy B.V., Stallergenes Greer, ALK-Abelló A/S, Allergy Therapeutics Plc, Torii Pharmaceutical Co., Ltd., and DESENTUM OY.

Immunotherapy is a preventive treatment for allergic reactions which are caused by substances such as grass pollens, house dust mites and bee venom. While providing immunotherapy treatment to patients, the dose of the drug is gradually increased to which the person is allergic. Immunotherapy also reduces the inflammation that characterizes rhinitis and asthma. Allergy shots, also known as subcutaneous immunotherapy (SCIT), is the most commonly used immunotherapy and this is the only treatment available that actually changes the immune system, making it possible to prevent development of new allergies and asthma.

Market Dynamics

Market players are involved in research and development activities for development of drugs for allergy immunotherapy and this is expected to drive growth of the Europe and Japan allergy immunotherapy market, over the forecast period. For instance, in May 2018, Stallergenes Greer, a biopharmaceutical company, announced positive results for its phase III clinical trial which was carried out, in order to evaluate the efficacy and safety of its sublingual allergy immunotherapy tablet STAGR320, for the treatment of house dust mite.

Key players are engaged in receiving approvals for their drugs, from the regulatory authorities and this is expected to drive growth of the Europe and Japan allergy immunotherapy market, over the forecast period. For instance, in November 2018, Stallergenes Greer, a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (US FDA), for the extension of the indication for Oralair, for the treatment of patients with grass pollen-induced allergic rhinitis.

Moreover, in September 2018, Torii Pharmaceutical Co., Ltd. announced that Japan’s Ministry of Health, Labour and Welfare had approved the New Drug Application (NDA) for the Japanese cedar sublingual allergy immunotherapy (SLIT) tablet, i.e, CEDARCURE.

Key features of the study:

  • This report provides an in-depth analysis of the Europe and Japan allergy immunotherapy market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the Europe and Japan allergy immunotherapy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Novartis International AG, Merck & Co., Inc., Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., HAL Allergy B.V., Stallergenes Greer, ALK-Abelló A/S, Allergy Therapeutics Plc, Torii Pharmaceutical Co., Ltd., DESENTUM OY
  • Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The Europe and Japan allergy immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe and Japan allergy immunotherapy market

Detailed Segmentation:

  • Europe and Japan Allergy Immunotherapy Market, By Treatment:
    • Subcutaneous Immunotherapy (SCIT)
    • Sublingual Immunotherapy (SLIT)
  • Europe and Japan Allergy Immunotherapy Market, By Allergy Type:
    • Allergy Rhinitis
    • Allergy Asthma
    • Pollen Allergies
      • Cedar
      • Birch
      • Oak
      • Others
    • Pet Allergy
      • Cats
      • Dogs
      • Other Pets
    • Birds Allergy
    • Others
  • Europe and Japan Allergy Immunotherapy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Europe and Japan Allergy Immunotherapy Market, By Region:
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Denmark
        • Sweden
        • Poland
        • Belgium
        • Netherlands
        • Russia
        • Rest of Europe
    • Japan
  • Company Profiles
    • Novartis International AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Merck & Co., Inc.
    • Aimmune Therapeutics, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • HAL Allergy B.V.
    • Stallergenes Greer
    • ALK-Abelló A/S
    • Allergy Therapeutics Plc
    • Torii Pharmaceutical Co., Ltd.
    • DESENTUM OY

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Europe and Japan allergy immunotherapy market is expected to exhibit a CAGR of 8.1% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 1,228.37 Mn in 2022.
Novartis International AG, Merck & Co., Inc., Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., HAL Allergy B.V., Stallergenes Greer, ALK-Abelló A/S, Allergy Therapeutics Plc, Torii Pharmaceutical Co., Ltd., and DESENTUM OY are some of the prominent players operating in the market.
The market is expected to be valued at US$ 2,293.56 Mn in 2030.
Europe is the prominent region in the market.
Subcutaneous Immunotherapy (SCIT) is the prominent segment among the treatment segment in the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo